de Vanguard Group Madrigal Pharmaceuticals MDGL Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | USD 1053 M | Vender |
1,808,894
-3,160
| -0.2% | -USD 1.61 M | 0.02% | 695 |
|
|
2025
Q3 | USD 831 M | Vender |
1,812,054
-65,227
| -3% | -USD 24.3 M | 0.01% | 790 |
|
|
2025
Q2 | USD 568 M | Comprar |
1,877,281
+187,170
| +11% | +USD 55.8 M | 0.01% | 958 |
|
|
2025
Q1 | USD 560 M | Vender |
1,690,111
-16,024
| -0.9% | -USD 5.27 M | 0.01% | 928 |
|
|
2024
Q4 | USD 526 M | Vender |
1,706,135
-127,633
| -7% | -USD 35.9 M | 0.01% | 1012 |
|
|
2024
Q3 | USD 389 M | Comprar |
1,833,768
+27,064
| +1% | +USD 6.92 M | 0.01% | 1189 |
|
|
2024
Q2 | USD 506 M | Comprar |
1,806,704
+137,898
| +8% | +USD 32.8 M | 0.01% | 982 |
|
|
2024
Q1 | USD 446 M | Comprar |
1,668,806
+94,064
| +6% | +USD 22.2 M | 0.01% | 1068 |
|
|
2023
Q4 | USD 364 M | Comprar |
1,574,742
+1,404
| +0.1% | +USD 246 k | 0.01% | 1166 |
|
|
2023
Q3 | USD 230 M | Comprar |
1,573,338
+107,816
| +7% | +USD 20.3 M | 0.01% | 1359 |
|
|
2023
Q2 | USD 339 M | Comprar |
1,465,522
+47,349
| +3% | +USD 12.8 M | 0.01% | 1159 |
|
|
2023
Q1 | USD 344 M | Comprar |
1,418,173
+151,798
| +12% | +USD 41.4 M | 0.01% | 1126 |
|
|
2022
Q4 | USD 368 M | Comprar |
1,266,375
+12,070
| +1% | +USD 1.18 M | 0.01% | 1052 |
|
|
2022
Q3 | USD 81.5 M | Comprar |
1,254,305
+22,322
| +2% | +USD 1.55 M | ﹤0.01% | 1917 |
|
|
2022
Q2 | USD 88.2 M | Comprar |
1,231,983
+16,570
| +1% | +USD 1.22 M | ﹤0.01% | 1900 |
|
|
2022
Q1 | USD 119 M | Comprar |
1,215,413
+92,352
| +8% | +USD 7.79 M | ﹤0.01% | 1845 |
|
|
2021
Q4 | USD 95.2 M | Comprar |
1,123,061
+51,531
| +5% | +USD 4.23 M | ﹤0.01% | 2009 |
|
|
2021
Q3 | USD 85.5 M | Comprar |
1,071,530
+22,220
| +2% | +USD 1.92 M | ﹤0.01% | 2070 |
|
|
2021
Q2 | USD 102 M | Comprar |
1,049,310
+51,501
| +5% | +USD 6.1 M | ﹤0.01% | 1991 |
|
|
2021
Q1 | USD 117 M | Comprar |
997,809
+109,391
| +12% | +USD 12.8 M | ﹤0.01% | 1870 |
|
|
2020
Q4 | USD 98.8 M | Comprar |
888,418
+121,914
| +16% | +USD 14.9 M | ﹤0.01% | 1840 |
|
|
2020
Q3 | USD 91 M | Vender |
766,504
-51,425
| -6% | -USD 5.58 M | ﹤0.01% | 1733 |
|
|
2020
Q2 | USD 92.6 M | Vender |
817,929
-16,772
| -2% | -USD 1.65 M | ﹤0.01% | 1721 |
|
|
2020
Q1 | USD 55.7 M | Comprar |
834,701
+49,260
| +6% | +USD 4.1 M | ﹤0.01% | 1825 |
|
|
2019
Q4 | USD 71.6 M | Vender |
785,441
-4,498
| -0.6% | -USD 436 k | ﹤0.01% | 1934 |
|
|
2019
Q3 | USD 68.1 M | Comprar |
789,939
+39,113
| +5% | +USD 3.67 M | ﹤0.01% | 1930 |
|
|
2019
Q2 | USD 78.7 M | Vender |
750,826
-30,450
| -4% | -USD 3.26 M | ﹤0.01% | 1878 |
|
|
2019
Q1 | USD 97.9 M | Comprar |
781,276
+34,300
| +5% | +USD 4.26 M | ﹤0.01% | 1759 |
|
|
2018
Q4 | USD 84.2 M | Comprar |
746,976
+40,658
| +6% | +USD 6.29 M | ﹤0.01% | 1778 |
|
|
2018
Q3 | USD 151 M | Comprar |
706,318
+243,664
| +53% | +USD 61.1 M | 0.01% | 1573 |
|
|
2018
Q2 | USD 129 M | Comprar |
462,654
+175,770
| +61% | +USD 30.9 M | 0.01% | 1643 |
|
|
2018
Q1 | USD 33.5 M | Comprar |
286,884
+12,525
| +5% | +USD 1.55 M | ﹤0.01% | 2274 |
|
|
2017
Q4 | USD 25.2 M | Comprar |
274,359
+130,916
| +91% | +USD 7.48 M | ﹤0.01% | 2400 |
|
|
2017
Q3 | USD 6.45 M | Comprar |
143,443
+64,059
| +81% | +USD 1.2 M | ﹤0.01% | 3011 |
|
|
2017
Q2 | USD 1.29 M | Vender |
79,384
-9,487
| -11% | -USD 148 k | ﹤0.01% | 3513 |
|
|
2017
Q1 | USD 1.37 M | Vender |
88,871
-46
| -0.1% | -USD 724 | ﹤0.01% | 3503 |
|
|
2016
Q4 | USD 1.32 M | Vender |
88,917
-12,916
| -13% | -USD 208 k | ﹤0.01% | 3494 |
|
|
2016
Q3 | USD 1.29 M | Vender |
101,833
-8,200
| -7% | -USD 79.4 k | ﹤0.01% | 3515 |
|
|
2016
Q2 | USD 1 M | Vender |
110,033
-7,449
| -6% | -USD 89.4 k | ﹤0.01% | 3602 |
|
|
2016
Q1 | USD 986 k | Vender |
117,482
-4,989
| -4% | -USD 41.7 k | ﹤0.01% | 3604 |
|
|
2015
Q4 | USD 1.51 M | Comprar |
122,471
+25,305
| +26% | +USD 694 k | ﹤0.01% | 3498 |
|
|
2015
Q3 | USD 5.92 M | Comprar |
97,166
+10,094
| +12% | +USD 728 k | ﹤0.01% | 2892 |
|
|
2015
Q2 | USD 6.8 M | Comprar |
87,072
+6,674
| +8% | +USD 560 k | ﹤0.01% | 2868 |
|
|
2015
Q1 | USD 5.46 M | Comprar |
80,398
+20,267
| +34% | +USD 1.74 M | ﹤0.01% | 2958 |
|
|
2014
Q4 | USD 5.58 M | Comprar |
60,131
+10,619
| +21% | +USD 1.1 M | ﹤0.01% | 2843 |
|
|
2014
Q3 | USD 5.22 M | Comprar |
49,512
+5,413
| +12% | +USD 753 k | ﹤0.01% | 2797 |
|
|
2014
Q2 | USD 6.31 M | Vender |
44,099
-152
| -0.3% | -USD 22.2 k | ﹤0.01% | 2723 |
|
|
2014
Q1 | USD 6.68 M | Comprar |
44,251
+3,404
| +8% | +USD 670 k | ﹤0.01% | 2686 |
|
|
2013
Q4 | USD 7.49 M | Comprar |
40,847
+9,706
| +31% | +USD 1.78 M | ﹤0.01% | 2582 |
|
|
2013
Q3 | USD 6.88 M | Comprar |
31,141
+1,063
| +4% | +USD 226 k | ﹤0.01% | 2576 |
|
|
2013
Q2 | USD 5.25 M | Comprar |
+30,078
| Nuevas | +USD 7.84 M | ﹤0.01% | 2637 |
|
Otros fondos que tienen MDGL en su cartera
BBA
Posición de Vanguard Group en MDGL: resumen de T4 2025
Vanguard Group redujo su participación en Madrigal Pharmaceuticals (MDGL) en 0.17% durante T4 2025, al vender acciones por un valor estimado de USD 1.61 M, y conservó 1,808,894 acciones valuadas en USD 1053 M. La posición representa 0.02% de la cartera y ocupa el puesto #695.
Vanguard Group reportó por primera vez una posición en MDGL en T2 2013 y la ha mantenido durante 51 trimestres desde entonces. Al cierre de T4 2025, 387 fondos que sigue Wall St. Rank mantienen una posición en MDGL.
- Al cierre de T4 2025, Vanguard Group tenía 1,808,894 acciones de Madrigal Pharmaceuticals con un valor de USD 1053 M.
- Vanguard Group vendió 3,160 acciones de Madrigal Pharmaceuticals en T4 2025, por un valor estimado de USD 1.61 M.
- Madrigal Pharmaceuticals representó 0.02% de la cartera de Vanguard Group en T4 2025 y fue su posición número 695.
- Vanguard Group reportó por primera vez una posición en Madrigal Pharmaceuticals en T2 2013 y la ha mantenido durante 51 trimestres desde entonces.
- Al cierre de T4 2025, 387 fondos que sigue Wall St. Rank tenían Madrigal Pharmaceuticals en cartera.
Según el Informe 13F de Vanguard Group correspondiente a T4 2025, presentado el 29 ene 2026.